UT Southwestern, Harold C. Simmons Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 12 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Landau, Heather
NCT03618537: Ixazomib Maintenance Study in Patients With AL Amyloidosis

Active, not recruiting
2
17
US
Ixazomib, Dexamethasone
Memorial Sloan Kettering Cancer Center, Tufts Medical Center, Vanderbilt University Medical Center
AL Amyloidosis
08/26
08/26
NCT02909036: Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

Active, not recruiting
1
46
US
Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
Memorial Sloan Kettering Cancer Center, Spectrum Pharmaceuticals, Inc
Multiple Myeloma, Amyloidosis
09/25
09/25
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients with Light Chain (AL) Amyloidosis

Recruiting
1
40
US
NXC-201 CAR-T, HBI0101 CAR-T
Nexcella Inc., Immix Biopharma, Inc.
Light Chain (AL) Amyloidosis
12/26
01/39
NCT06126341: A Study to Identify Barriers to Cellular Therapies for People with Plasma Cell Disorders

Recruiting
N/A
400
US
Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM, Hospital Anxiety and Depression Scale, HADS, Duke-UNC Functional Social Support Questionnaire, Distress Thermometer, DT, FACT-BMT, Psychosocial Assessments of Candidates for Transplantation, PACT
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
05/29
05/29
NCT06365060: Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Recruiting
N/A
400
US
Tufts Medical Center, National Cancer Institute (NCI)
Smoldering Multiple Myeloma
02/29
02/29
NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation

Recruiting
N/A
91
US
Home monitoring teleconsult visits, Patient Reported Outcomes (PRO), Caregiver Reported Outcomes instruments
Memorial Sloan Kettering Cancer Center
Plasma Cell Dyscrasia
01/27
01/27
Tuchman, Sascha
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
DETER-SMM, NCT03937635: Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Recruiting
3
288
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
12/29
12/29
NCT06179888: Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Recruiting
2
78
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Iberdomide, CC 220, CC-220, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Patient Monitoring, medical monitoring, monitor, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Skeletal Survey X-Ray, Skeletal Survey
National Cancer Institute (NCI)
Multiple Myeloma
10/27
10/27
NCT04009109: Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Active, not recruiting
2
79
US
Lenalidomide, Revlimid, Ixazomib, Ninlaro, Daratumumab Injection, Darzalex, Dexamethasone, Ozurdex
Alliance Foundation Trials, LLC., Janssen Scientific Affairs, LLC, Celgene Corporation, Takeda
Myeloma, Multiple
10/25
07/26
NCT05145400: Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Recruiting
2
50
US
Isatuximab, Lenalidomide, REVLIMID, Dexamethasone
UNC Lineberger Comprehensive Cancer Center, Genzyme, a Sanofi Company
Multiple Myeloma, Cancer
03/26
03/31
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
NCT03672318: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
25
US
CAR138 T Cells, ATLCAR.CD138, CAR.CD138 T cells
UNC Lineberger Comprehensive Cancer Center, Baylor College of Medicine, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Multiple Myeloma, Immune System Diseases
10/24
08/39
DREAMM 12, NCT04398745: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Recruiting
1
36
Europe, US, RoW
Belantamab mafodotin, GSK2857916
GlaxoSmithKline
Multiple Myeloma
02/25
02/25
NCT04615572: Screening to Improve Survival in AL Amyloidosis

Completed
N/A
35
US
Tufts Medical Center, National Institute on Aging (NIA)
Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
07/23
07/23
NCT06365060: Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Recruiting
N/A
400
US
Tufts Medical Center, National Cancer Institute (NCI)
Smoldering Multiple Myeloma
02/29
02/29
LCCC 1728, NCT03717844: Registry for Adults With Plasma Cell Disorders (PCD's)

Recruiting
N/A
2000
US
UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease, Light Chain Deposition Disease, Heavy Chain Deposition Disease, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma, Plasma Cell Leukemia
02/28
02/29
Axelrod, Bayley
NCT06365060: Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Recruiting
N/A
400
US
Tufts Medical Center, National Cancer Institute (NCI)
Smoldering Multiple Myeloma
02/29
02/29

Download Options